Peak Plasma Concentration of Nebulized Budesonide
The peak plasma concentration after nebulized budesonide is approximately 2.6 nmol/L (approximately 300-435 pg/mL depending on formulation), occurring 20 minutes to 3 hours post-administration, with newer submicron formulations achieving peak levels more rapidly than traditional suspensions.
Pharmacokinetic Profile
Peak Concentration Values
Based on FDA-approved labeling and clinical pharmacokinetic studies, the peak plasma concentrations vary by formulation and dose:
Standard budesonide inhalation suspension (1 mg dose): Peak concentration of 2.6 nmol/L achieved approximately 20 minutes after nebulization in children 4-6 years of age 1
Commercial budesonide suspension (0.25 mg): Peak concentration of 303.5 ± 177.4 pg/mL with median time to peak of 9.1 ± 7.1 minutes 2
Nanocrystal budesonide formulations (0.5 mg): Demonstrate similar or higher peak concentrations with more rapid absorption compared to traditional suspensions 3
Time to Peak Concentration (Tmax)
The timing of peak plasma levels is formulation-dependent:
- Submicron/nanocrystal formulations: Achieve peak concentrations in 3-4.5 minutes, significantly faster than traditional suspensions 2
- Traditional budesonide suspensions: Peak at approximately 9 minutes 2
- FDA-labeled standard formulation: Peaks at 20 minutes in pediatric patients 1
Systemic Bioavailability Context
Critical clinical consideration: The low systemic bioavailability of nebulized budesonide (approximately 6% of nominal dose in children, 15-17% in adults) means these peak concentrations represent minimal systemic exposure 1, 4, 5. This is due to:
- Extensive first-pass hepatic metabolism
- Only lung-deposited drug reaches systemic circulation
- Swallowed portion undergoes 90% hepatic first